August 26, 2020 10:38 AM EDT

A Forbion-funded startup bought the rights to Amgen's CETP inhibitor, and is giving the cholesterol drug another go

Nicole DeFeudis

Editor

Forbion-funded startup NewAmsterdam Pharma has acquired the rights to obicetrapib: the CETP inhibitor that CEO Michael Davidson always thought would be the “crowning” of his …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

A Forbion-funded startup bought the rights to Amgen's CETP inhibitor, and is giving the cholesterol drug another go

Nicole DeFeudis

Editor

Sign up to read this article for free.

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

'Go ahead and do it': Top RFK Jr. deputy dares drugmakers that might pull manufacturing over new price pressure

The inside story of the six-month sprint to create the first custom CRISPR therapy for one infant’s rare disease

New CBER chief Prasad is readying 'massive framework' around vaccines, Makary says

Bristol Myers CEO says America’s biopharma pole position is not guaranteed

Exclusive: Drug compounder Empower was built on risky shortcuts, ex-employees and inspections allege

Eli Lilly turns to South Korean RNA editing biotech for hearing loss in deal worth $1.3B

A For­bion-fund­ed start­up bought the rights to Am­gen's CETP in­hibitor, and is giv­ing the cho­les­terol drug an­oth­er go

Editor

Sign up to read this article for free.

more like this

Autonomy Bio Inc.

San Francisco, CA 94107, USA

A Forbion-funded startup bought the rights to Amgen's CETP inhibitor, and is giving the cholesterol drug another go